Terameprocol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Terameprocol
DrugBank Accession Number
DB12226
Background

Terameprocol has been investigated for the treatment of Brain and Central Nervous System Tumors.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 358.478
Monoisotopic: 358.214409446
Chemical Formula
C22H30O4
Synonyms
  • meso-Tetra-O-methylnordihydroguaiaretic acid
  • meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
  • Terameprocol
External IDs
  • EM 1421
  • EM-1421

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dibenzylbutane lignans. These are lignan compounds containing a 2,3-dibenzylbutane moiety.
Kingdom
Organic compounds
Super Class
Lignans, neolignans and related compounds
Class
Dibenzylbutane lignans
Sub Class
Not Available
Direct Parent
Dibenzylbutane lignans
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / Hydrocarbon derivatives
Substituents
Alkyl aryl ether / Anisole / Aromatic homomonocyclic compound / Benzenoid / Dibenzylbutane lignan skeleton / Dimethoxybenzene / Ether / Hydrocarbon derivative / Methoxybenzene / Monocyclic benzene moiety
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
53YET703F2
CAS number
24150-24-1
InChI Key
ORQFDHFZSMXRLM-IYBDPMFKSA-N
InChI
InChI=1S/C22H30O4/c1-15(11-17-7-9-19(23-3)21(13-17)25-5)16(2)12-18-8-10-20(24-4)22(14-18)26-6/h7-10,13-16H,11-12H2,1-6H3/t15-,16+
IUPAC Name
4-[(2R,3S)-3-[(3,4-dimethoxyphenyl)methyl]-2-methylbutyl]-1,2-dimethoxybenzene
SMILES
COC1=CC=C(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)C=C1OC

References

General References
Not Available
PubChem Compound
476861
PubChem Substance
347828505
ChemSpider
418597
ChEMBL
CHEMBL90983
ZINC
ZINC000016953163

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHigh Grade Glioma (III or IV)1
1CompletedTreatmentMalignancies1
1CompletedTreatmentNeoplasms, Head and Neck1
1TerminatedTreatmentAcute Lymphoblastic Leukemia (ALL) / Acute Myeloid Leukemia (AML) / Adult T Cell Leukemia (ATL) / Chronic Lymphocytic Leukemia (CLL) / Chronic Myeloid Leukemia (CML-BP) / Chronic Myelomonocytic Leukemia (CMML) / Leukemias / Myelodysplastic Syndromes (MDS)1
1TerminatedTreatmentMalignant Lymphomas / Refractory Solid Tumors1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCervical Intraepithelial Neoplasia (CIN)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000192 mg/mLALOGPS
logP5.77ALOGPS
logP5.34ChemAxon
logS-6.3ALOGPS
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.92 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity104.55 m3·mol-1ChemAxon
Polarizability41.9 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 21:40 / Updated on February 21, 2021 18:53